IONS
Ionis Pharmaceuticals, Inc.
80.66
1 x 74.47
1 x 80.97
bid
ask
+
1.47
1.86%
10:16 AM
timesize
| Ytd | 1.96% | |
| 1y | 85.04% |
79.11
day range
80.99
40.03
52 week range
86.74
| Open | 79.53 | Prev Close | 79.19 | Low | 79.11 | High | 80.99 | Mkt Cap | 13.35B |
| Vol | 155.47K | Avg Vol | 1.82M | EPS | -2.01 | P/E | N/A | Forward P/E | -130.13 |
| Beta | 0.37 | Short Ratio | 10.30 | Inst. Own | 107.26% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 75.32 | 200-d Avg | 75.65 | 1yr Est | 105.91 |
| Income Statement | |||
| Total Revenue | 246.09M | ||
| Revenues (USD) | 246.09M | ||
| Cost of Revenue | 2.98M | ||
| Gross Profit | 243.11M | ||
| Operating Expenses | 360.53M | ||
| Research and Development Expense | 210.17M | ||
| Selling, General and Administrative Expense | 150.36M | ||
| Operating Income | -117.42M | ||
| Interest Expense | 22.50M | ||
| Income Tax Expense | 218.00K | ||
| Net Income | -92.53M | ||
| Net Income Common Stock | -92.53M | ||
| Net Income Common Stock (USD) | -92.53M | ||
| Consolidated Income | -92.53M | ||
| Earnings per Basic Share | -0.56 | ||
| Earnings per Basic Share (USD) | -0.56 | ||
| Earnings per Diluted Share | -0.56 | ||
| Earning Before Interest & Taxes (EBIT) | -69.81M | ||
| Earning Before Interest & Taxes (USD) | -69.81M | ||
| Weighted Average Shares | 164.87M | ||
| Weighted Average Shares Diluted | 164.87M | ||
| Balance Sheet | |||
| Cash and Equivalents | 173.38M | ||
| Cash and Equivalents (USD) | 173.38M | ||
| Investments | 1.75B | ||
| Investments Current | 1.75B | ||
| Trade and Non-Trade Receivables | 73.68M | ||
| Current Assets | 2.94B | ||
| Property, Plant & Equipment Net | 377.47M | ||
| Total Assets | 3.45B | ||
| Debt Current | 432.50M | ||
| Total Debt | 2.04B | ||
| Current Liabilities | 716.59M | ||
| Debt Non-Current | 1.61B | ||
| Total Liabilities | 2.96B | ||
| Accumulated Retained Earnings (Deficit) | -2.72B | ||
| Accumulated Other Comprehensive Income | -31.02M | ||
| Shareholders Equity | 491.41M | ||
| Shareholders Equity (USD) | 491.41M | ||
| Assets Non-Current | 513.02M | ||
| Total Debt (USD) | 2.04B | ||
| Deferred Revenue | 144.94M | ||
| Inventory | 5.56M | ||
| Liabilities Non-Current | 2.24B | ||
| Trade and Non-Trade Payables | 26.03M | ||
| Tax Liabilities | 2.87M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 7.45M | ||
| Net Cash Flow from Financing | 57.26M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -198.88M | ||
| Capital Expenditure | -21.76M | ||
| Issuance (Purchase) of Equity Shares | 57.30M | ||
| Issuance (Repayment) of Debt Securities | -44.00K | ||
| Net Cash Flow from Investing | 536.82M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 560.07M | ||
| Net Cash Flow from Operations | -792.82M | ||
| Effect of Exchange Rate Changes on Cash | -138.00K | ||
| Share Based Compensation | 43.28M | ||